News-Medical.Net on MSN
PSA-based tool improves decision making for prostate cancer screening and treatment
In a previous study, the researchers showed that PSA scores can impact both doctor and patient behavior, leading to biopsy ...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...
An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic ...
A new long-term prediction tool estimates the risk of dying from prostate cancer, offering a more accurate way to interpret ...
GG1 prostate cancer can have heterogeneous outcomes, with some patients having intermediate- or high-risk disease, challenging the notion of GG1 as uniformly low-risk. Removing the cancer label for ...
Talzenna plus Xtandi showed a 14-month survival improvement for HRR gene-mutated metastatic castration-resistant prostate cancer, supported by TALAPRO-2 trial data. Nubeqa approval for metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback